Raju Mohan
Founder at VENTYX BIOSCIENCES, INC.
Net worth: 6 M $ as of 2024-04-29
Profile
Raju S.
Mohan is the founder.
He founded Zomagen Biosciences Ltd.
in 2018, Akarna Therapeutics Ltd.
in 2014, Ventyx Biosciences, Inc. in 2018, and Vimalan Biosciences, Inc. in 2017.
Dr. Mohan is also the founder of Escalier Biosciences BV.
Dr. Mohan's current job(s) include being a Director at Oppilan Pharma Ltd.
since 2015 and a Partner & Senior Advisor at New Science Ventures LLC since 2017.
Dr. Mohan's former job(s) include being the Vice President & Head-San Diego Site at Exelixis, Inc. from 2006 to 2011 and the Vice President-Chemistry at X-Ceptor Therapeutics, Inc. from 2004 to 2006.
Dr. Mohan's education history includes graduating from the Indian Institute of Technology Bombay and obtaining a doctorate degree from the University of Illinois At Urbana–Champaign.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VENTYX BIOSCIENCES, INC.
2.24% | 2024-04-10 | 1,578,250 ( 2.24% ) | 6 M $ | 2024-04-29 |
Raju Mohan active positions
| Companies | Position | Start |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Founder | 2018-10-31 |
Oppilan Pharma Ltd.
 Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 2015-05-26 |
Escalier Biosciences BV
 Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Founder | - |
New Science Ventures LLC
 New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Private Equity Investor | 2016-12-31 |
| Vimalan Biosciences, Inc. | Founder | 2017-09-30 |
Former positions of Raju Mohan
| Companies | Position | End |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | 2010-12-31 |
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 2005-12-31 |
| Zomagen Biosciences Ltd. | Founder | - |
Akarna Therapeutics Ltd.
 Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Founder | - |
Training of Raju Mohan
| Indian Institute of Technology Bombay | Graduate Degree |
| University of Illinois At Urbana–Champaign | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| VENTYX BIOSCIENCES, INC. | Health Technology |
| EXELIXIS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Akarna Therapeutics Ltd.
Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Oppilan Pharma Ltd.
Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Health Technology |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Health Technology |
New Science Ventures LLC
New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Finance |
| Vimalan Biosciences, Inc. | |
| Zomagen Biosciences Ltd. | |
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Raju Mohan
